Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation.

Saito T, Gutiérrez Rico EM, Kikuchi A, Kaneko A, Kumondai M, Akai F, Saigusa D, Oda A, Hirasawa N, Hiratsuka M.

Drug Metab Pharmacokinet. 2018 Dec;33(6):250-257. doi: 10.1016/j.dmpk.2018.08.004. Epub 2018 Aug 25.

PMID:
30366777
2.

Development and application of a rapid and sensitive genotyping method for pharmacogene variants using the single-stranded tag hybridization chromatographic printed-array strip (STH-PAS).

Kumondai M, Ito A, Hishinuma E, Kikuchi A, Saito T, Takahashi M, Tsukada C, Saito S, Yasuda J, Nagasaki M, Minegishi N, Yamamoto M, Kaneko A, Teramoto I, Kimura M, Hirasawa N, Hiratsuka M.

Drug Metab Pharmacokinet. 2018 Dec;33(6):258-263. doi: 10.1016/j.dmpk.2018.08.003. Epub 2018 Aug 22.

PMID:
30269962
3.

An optimized prediction framework to assess the functional impact of pharmacogenetic variants.

Zhou Y, Mkrtchian S, Kumondai M, Hiratsuka M, Lauschke VM.

Pharmacogenomics J. 2018 Sep 12. doi: 10.1038/s41397-018-0044-2. [Epub ahead of print]

PMID:
30206299
4.

Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation.

Watanabe T, Saito T, Rico EMG, Hishinuma E, Kumondai M, Maekawa M, Oda A, Saigusa D, Saito S, Yasuda J, Nagasaki M, Minegishi N, Yamamoto M, Yamaguchi H, Mano N, Hirasawa N, Hiratsuka M.

Biochem Pharmacol. 2018 Oct;156:420-430. doi: 10.1016/j.bcp.2018.09.010. Epub 2018 Sep 8.

PMID:
30201214
5.

Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation.

Kumondai M, Hosono H, Maekawa M, Yamaguchi H, Mano N, Oda A, Hirasawa N, Hiratsuka M.

Drug Metab Pharmacokinet. 2018 Feb;33(1):82-89. doi: 10.1016/j.dmpk.2017.11.004. Epub 2017 Nov 22.

PMID:
29342418
6.

Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics.

Santos M, Niemi M, Hiratsuka M, Kumondai M, Ingelman-Sundberg M, Lauschke VM, Rodríguez-Antona C.

Genet Med. 2018 Jun;20(6):622-629. doi: 10.1038/gim.2017.156. Epub 2017 Oct 26.

PMID:
29261188
7.

Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities.

Hosono H, Kumondai M, Maekawa M, Yamaguchi H, Mano N, Oda A, Hirasawa N, Hiratsuka M.

Drug Metab Dispos. 2017 Mar;45(3):279-285. doi: 10.1124/dmd.116.073494. Epub 2016 Dec 14.

8.

CYP2A13 Genetic Polymorphisms in Relation to the Risk of Bladder Cancer in Japanese Smokers.

Kumondai M, Hosono H, Orikasa K, Arai Y, Arai T, Sugimura H, Ozono S, Sugiyama T, Takayama T, Sasaki T, Hirasawa N, Hiratsuka M.

Biol Pharm Bull. 2016;39(10):1683-1686.

9.

Genetic Polymorphisms of CYP2A6 in a Case-Control Study on Bladder Cancer in Japanese Smokers.

Kumondai M, Hosono H, Orikasa K, Arai Y, Arai T, Sugimura H, Ozono S, Sugiyama T, Takayama T, Sasaki T, Hirasawa N, Hiratsuka M.

Biol Pharm Bull. 2016;39(1):84-9. doi: 10.1248/bpb.b15-00604.

10.

CYP2A6 genetic polymorphism is associated with decreased susceptibility to squamous cell lung cancer in Japanese smokers.

Hosono H, Kumondai M, Arai T, Sugimura H, Sasaki T, Hirasawa N, Hiratsuka M.

Drug Metab Pharmacokinet. 2015 Aug;30(4):263-8. doi: 10.1016/j.dmpk.2015.04.002. Epub 2015 Apr 18.

PMID:
26091970

Supplemental Content

Loading ...
Support Center